genitourinary tumours, prostate Final overall survival (OS) from the AFFINITY phase 3 trial of custirsen and cabazitaxel/prednisone in men with previously treated metastatic castration-resistant prostate cancer (mCRPC)

Phase 3 ◽

Castration Resistant ◽

Previously Treated

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(12)70379-0 ◽

2012 ◽

Vol 13 (10) ◽

pp. 983-992 ◽

Cited By ~ 773

Author(s):

Karim Fizazi ◽

Howard I Scher ◽

Arturo Molina ◽

Christopher J Logothetis ◽

Kim N Chi ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Abiraterone Acetate ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Overall Survival Analysis

Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30605-8 ◽

2017 ◽

Vol 18 (11) ◽

pp. 1532-1542 ◽

Cited By ~ 38

Author(s):

Tomasz M Beer ◽

Sebastien J Hotte ◽

Fred Saad ◽

Boris Alekseev ◽

Vsevolod Matveev ◽

...

Keyword(s):

Prostate Cancer ◽

Open Label ◽

Phase 3 ◽

Castration Resistant ◽

Previously Treated

7000 ORAL Final Overall Survival (OS) Analysis of COU-AA-301, a Phase 3 Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Pretreated With Docetaxel

European Journal of Cancer ◽

10.1016/s0959-8049(11)71951-7 ◽

2011 ◽

Vol 47 ◽

pp. S483-S484 ◽

Cited By ~ 7

Author(s):

K. Fizazi ◽

H.I. Scher ◽

A. Molina ◽

C.J. Logothetis ◽

R.J. Jones ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Abiraterone Acetate ◽

Phase 3 ◽

Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Long-term overall survival and safety analyses of the phase 3 PREVAIL study

European Urology Supplements ◽

10.1016/s1569-9056(19)30874-7 ◽

2019 ◽

Vol 18 (1) ◽

pp. e1217-e1218

Author(s):

A. Armstrong ◽

B. Tombal ◽

F. Saad ◽

T. Parli ◽

D. Phung ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Phase 3 ◽

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(14)71205-7 ◽

2015 ◽

Vol 16 (2) ◽

pp. 152-160 ◽

Cited By ~ 642

Author(s):

Charles J Ryan ◽

Matthew R Smith ◽

Karim Fizazi ◽

Fred Saad ◽

Peter F A Mulders ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Abiraterone Acetate ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Overall Survival Analysis

Updated Overall Survival (Os) from the Phase 3 Trial, Ca184-043: Ipilimumab (Ipi) Vs Placebo (Pbo) in Patients with Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer (Mcrpc)

Annals of Oncology ◽

10.1093/annonc/mdu336.11 ◽

2014 ◽

Vol 25 ◽

pp. iv259 ◽

Cited By ~ 7

Author(s):

K. Fizazi ◽

C.G. Drake ◽

E.D. Kwon ◽

A. Bossi ◽

A.J. van den Eertwegh ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Phase 3 ◽

Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer

JAMA Oncology ◽

10.1001/jamaoncol.2018.1093 ◽

2018 ◽

Vol 4 (7) ◽

pp. 944 ◽

Cited By ~ 30

Author(s):

Andrew J. Armstrong ◽

Aseem Anand ◽

Lars Edenbrandt ◽

Eva Bondesson ◽

Anders Bjartell ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Bone Scan ◽

Imaging Biomarker ◽

Bone Scan Index ◽

Phase 3 ◽

Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data

Prostate Cancer and Prostatic Diseases ◽

10.1038/s41391-021-00326-3 ◽

2021 ◽

Author(s):

Alberto Martini ◽

Anish B. Parikh ◽

John P. Sfakianos ◽

Francesco Montorsi ◽

Matthew D. Galsky ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Overall Survival ◽

Clinical Trial Data ◽

Pooled Analysis ◽

Trial Data ◽

Phase 3 ◽

Open Phase ◽

Final Overall Survival (Os) Analysis of Cou-Aa-302, a Randomized Phase 3 Study of Abiraterone Acetate (Aa) in Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients (Pts) Without Prior Chemotherapy

Annals of Oncology ◽

10.1093/annonc/mdu336.1 ◽

2014 ◽

Vol 25 ◽

pp. iv255 ◽

Cited By ~ 23

Author(s):

C.J. Ryan ◽

M.R. Smith ◽

K. Fizazi ◽

K. Miller ◽

P. Mulders ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Abiraterone Acetate ◽

Phase 3 ◽

Prior Chemotherapy ◽

Faculty Opinions recommendation of Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717955961.793460904 ◽

2012 ◽

Author(s):

Bruno Andreoni ◽

Gianmarco Contino

Keyword(s):

Prostate Cancer ◽

Controlled Study ◽

Phase 3 ◽